Testing Contezolid for Bone and Joint Tuberculosis
Treatments studied
Part of Infections clinical trials.
This trial tests an antibiotic called contezolid for people with bone or joint tuberculosis. It aims to see if the drug can treat the infection effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bone or joint tuberculosis in the last 3 months.
- You have not been on steroids or immune-suppressing medicines in the last 90 days.
- You are not pregnant, breastfeeding, or recently postpartum.
- You must agree to use effective birth control during the study and for one month after.
- You have no known allergy to contezolid or linezolid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic called contezolid for people with tuberculous meningitis, an infection of the brain lining. The goal is to see if it works well and is safe.
This trial tests how quickly two antibiotics (tedizolid vs linezolid) can kill tuberculosis germs in the lungs after a first TB infection is suspected. It may help doctors learn which option works faster and safely in the early treatment phase.
This trial looks at patterns of gene activity (from blood/tissue samples) in adults with spinal tuberculosis. The goal is to better understand the disease and how to tell different conditions apart, which may help future care.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This trial tests a new tablet called JDB0131 for people with tuberculosis (TB) that is resistant to the antibiotic rifampicin. The goal is to see if it can effectively treat this hard-to-treat form of TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.